Machine Learning and Artificial Intelligence in Nanomedicine
Wei‐Chun Chou, Alexa Canchola, Fan Zhang, Zhoumeng Lin
University of California, Riverside University of Florida University of Florida Health
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
Nanomedicine harnesses nanoscale materials, such as lipid, polymeric, and inorganic nanoparticles, to deliver diagnostic or therapeutic agents for cancer, infectious disease, and neurological disorders, among others. However, translating promising nanoparticle designs into clinically approved products remains a challenge. Factors such as particle size, surface chemistry, and payload interactions must be optimized, and preclinical results often fail to predict human efficacy. In recent years, artificial intelligence (AI) and machine learning (ML) have emerged as transformative tools to address these hurdles at every stage of nanomedicine development. By rapidly screening extensive libraries and extracting structure-function relationships, AI-driven models can rationalize nanoparticle formulation, predict biodistribution, and guide optimal design. Techniques like high-throughput DNA barcoding and automated liquid handling facilitate robust, large-scale data collection, feeding into computational pipelines that expedite discovery while reducing reliance on resource-intensive trial-and-error experiments. AI-based platforms also enable improved modeling of protein corona formation, which profoundly affects nanoparticle immunogenicity and cellular uptake. Despite these advances, challenges persist in data standardization, model generalizability, and establishing a clear regulatory framework since no dedicated U.S. Food and Drug Administration (FDA) guidance addresses the intersection of AI and nanomedicine. Overcoming these limitations requires harmonized data sharing, rigorous in vivo validation, and clear ethical and regulatory guidelines. This review summarizes the rapidly evolving landscape of AI in nanomedicine, highlighting key successes in design and preclinical prediction, as well as persistent obstacles to full-scale clinical integration. By illuminating these dynamics, we aim to chart a more efficient path forward in developing next-generation nanomedicine.
逐年被引趋势
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
工程Graphene and Nanomaterials Applications
Nanoparticle-Based Drug Delivery · Nanotechnology research and applications
参考文献 115
此处列出前 3 条
引用本文 124
按被引量排序,此处列出前 3 条